Skip main navigation

Home > Search Results

Main contents starts here

Search Results

1 - 20 of about 358

Total 358 documents found.

  •  
  • Takeda Ireland Limited
  • Takeda Ireland Limited (TIL) has played a key role in Takeda's worldwide operations since 1997. We began manufacturing in Ireland following the opening of our custom built premises in 1999. Since the first shipment of Blopress/Amias in September 1999, we have served as Takeda's main pharmaceutical production base for the European and U.S. markets. No year has passed when we have not been involved in construction and equipment expansion projects in order to meet the increasing demands of Takeda's new products and ever-increasing demand.
  • Takeda Clinical Research Singapore Private Limited
  • TCRS is serving as a center of clinical development in the Asia-Oceania region and is responsible for clinical development operations in that region, in close coordination with the Takeda Pharmaceutical Company Limited, Takeda Global Research & Development Center Inc. in the United States, and Takeda Global Research & Development Centre (Europe) Limited.TCRS will complement the global R&D network of the Takeda Group, covering Japan, the U.S. Europe and Asia, and contribute to further enhancement of our overall R&D pipeline.
  • Relationship with Suppliers
  • Takeda ensures that the "Guidance for Purchasing Affairs," which was prepared based on the "Basic Purchasing Policy," is fully adhered to by all staff related to purchasing activities to facilitate smooth purchasing operation and enhance its function.
  • Energy Conservation / Prevention of Global Warming
  • The Fourth Assessment Report has been released by the Intergovernmental Panel on Climate Change (IPCC), reporting that greenhouse gases due to human activities impact on global warming. The initial commitment period (2008-2012) of the Kyoto Protocol - an agreement which establishes goals for reducing greenhouse gas emissions - is going to become effective next year and Takeda considers that ensuring a steady implementation of these efforts toward the goal of reducing total greenhouse gas emissions is our responsibility for the next generation.Manufacturing pharmaceutical products requires less energy consumption compared to other industries and its percentage of total greenhouse gas emissions is relatively low. However, it is true that during each stage of our operations, including the procurement of raw materials, manufacture, distribution and disposal, we release greenhouse gases into the air, which has an impact on the global warming regardless of the volume. In accordance with global warming, an increase of tropical diseases and emerging infectious diseases has been predicted; therefore, as a pharmaceutical manufacturer, playing a role in the medical services domain, Takeda recognizes the significance of efforts to boost global warming prevention.
  • Takeda Expands International Operations Leadership July 30, 2010
  • Osaka, Japan, July 30, 2010 -Takeda Pharmaceutical Company Limited ("Takeda") today announced that effective August 1, 2010 the International Operations organization will be further strengthened with the appointment of a Senior Vice President (SVP) responsible for ex-Japan Asia commercial activities. This change will further enhance the company’s structure to accelerate Takeda’s global strategies and enable the management team in each region to most effectively address the local business environment.
  • ANNUALREPORT2009TakedaPharmaceuticalCompanyLimited Annual Report 2009 Our Contribution to Financial and Social Responsibility Editorial Policy Takeda integrates its annual report and CSR report into a single publication with a mind to give readers a complete understanding of how our business operations are guided by Takeda-ism and other elements of our corporate philosophy. Contributes to the Health of Individuals Takeda has been supplying pharmaceuticals for more than 220 years while never forgetting the importance of protecting and preserving life. Over the years, we have developed a strong commitment to the highest ethical standards and strong sense of mission. As our operations became global in scale, demands concerning corporate social responsibility (CSR) increased. We believe that developing superior pharmaceutical products in accordance with the principles of Takeda-ism is the essence of CSR for the Takeda Group. Due to this strong link between our business activities and CSR, since fiscal 2006, Take
  • Annual Report 2009 Based on Takeda-ism Relationship with Our Stakeholders CSR Data Book Annual Report 2009 1 CSR Data Book 2 12 14 16 18 20 22 24 26 Relationship with Society Relationship with Environment Relationship with Suppliers Relationship with Employees 8 Quality Assurance System 56 Stakeholders' Voices Employees Who Embody the Takeda-ism Ideals 28 30 32 33 34 36 37 38 40 42 43 44 46 48 50 52 54 4 Scope of Reporting Participating in the United Nations Global Compact Annual Report 2009 - Takeda Pharmaceutical Company Limited Table of Contents Editorial Policy Basic Policy on CSR / CSR Promotion Framework / CSR Activities in Fiscal 2009 Feature Feature: Access to Healthcare in Asia (Activities in Asia) Takeda's Corporate Citizenship Activities Activities in the U.S. Activities in France and Germany Activities in Italy and the UK Activities in Japan and Taiwan Activities in the Philippines and Thailand Other Activities Feature: Supply Chain Management Basic Purchasing Policy / Green Procurement and CSR P
  • Takeda to Create Global Centers of Excellence
    Reorganization helps Takeda realize globalization vision March 31, 2009
  • Osaka, Japan, March 31, 2009 -Takeda Pharmaceutical Company Limited ("Takeda") today announced a reorganization of its corporate structure, as part of its 2006-2010 Medium-Term Plan vision to become a global pharmaceutical company with highly integrated global operations. In order to become more responsive to rapid changes in the global operating environment and to maximize the global market potential of new products and the company’s global presence, the company is streamlining executive reporting relationships to Yasuchika Hasegawa, President, by creating corporate-level, center of excellence R&D, commercial and administrative functions. Effective April 1, 2009, Shigenori Ohkawa, Ph.D., will become Chief Scientific Officer (CSO), and Alan MacKenzie will become Executive Vice President (EVP) International Operations. Additionally, a Chief Administrative Officer (CAO) role will be established.
  • Takeda Expands its Own Sales and Marketing Operations in Europe March 30, 2009
  • Osaka, Japan & London, United Kingdom, March 30, 2009 – Takeda Pharmaceutical Company Limited (Osaka, Japan, “Takeda”) and its wholly-owned UK-based subsidiary for overseeing pan-European sales & marketing, Takeda Pharmaceutical Europe Limited (London, UK, “TPEU”) jointly announced today the start of its own sales and marketing operations in Spain, and also the expansion of its operations in the Republic of Ireland to cover the entire country, which used to be limited in a specific area.
  • ANNUALREPORT2008 Annual Report 2008 Our Contribution to Financial and Social Responsibility TakedaPharmaceuticalCompanyLimited Contributes to The Health of Individuals Worldwide 1 This annual report includes forward-looking statements regarding Takeda's plans, prospects, strategies and accomplishments, etc. These prospects are the result of assessment obtained from information currently available, and since the actual performance could be influenced by various risks and uncertainties, it shall be noted that the course of action could differ substantially from those prospects. Factors that could affect future prospects would include, but are not limited to, economic circumstances surrounding Takeda's domain identity, competitive pressures, relevant laws and regulations, change in the status of product development, exchange rate risk and so on. Precautions Regarding Forward-Looking Statements Takeda has issued an integrated Annual and CSR Report since fiscal 2006, in order to facilitate a comprehensive underst
  • Takeda Established a New Company for Clinical Development in the Asia-Oceania Region September 25, 2008
  • Osaka, Japan, September 25, 2008--- Takeda Pharmaceutical Company Limited ("Takeda") today announced the establishment of a wholly-owned subsidiary, "Takeda Clinical Research Singapore Private Limited." (TCRS) in the Republic of Singapore to serve as its center of clinical development in the Asia-Oceania region. TCRS will be responsible for clinical development operations in that region, in close coordination with the Takeda Pharmaceutical Company Limited, Takeda Global Research & Development Center Inc. in the United States, and Takeda Global Research & Development Centre (Europe) Limited.
  • CEO of a New Company for European Operations Appointed December 5, 2006
  • Osaka, Japan, December 5, 2006 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that, on December 1, Mr. Giacomo Di Nepi joined Takeda as CEO of the new company for Takeda European Operations, Takeda Pharmaceuticals Europe Limited ("TPEU"), which was established as a wholly owned subsidiary in last August and is now starting its activities.
  • Takeda to Establish New Research Facility in Fujisawa, Japan October 25, 2006
  • October 25, 2006, Osaka, Japan --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that it will establish new research facility in Fujisawa city, Kanagawa prefecture, integrating the current research facilities in Osaka city and Tsukuba city, Ibaragi prefecture. The new facility is planned to start the operation in fiscal year of 2010.
  • Takeda to Establish a New Company for European Sales & Marketing June 27, 2006
  • Osaka, Japan, June 27, 2006 --- Takeda Pharmaceutical Company Limited ("Takeda") today announced that it will establish a new company for European sales & marketing, ("The New Company") in London, UK. The establishment of The New Company is a part of initiatives for solidifying marketing structure in three regions (Japan, USA, Europe) and for conducting self-sustaining and appropriate operations for respective markets. That is one of the management tasks set forth in Takeda's 2006-2010 Medium-Term Management Plan.

Pages:[1] [2] [3] [4] [5] [6] [7] [8] [9] [10]   Next

Page Top